The use of KIR favorable TCRαβ/CD19-depleted haploidentical HSCT leads to 80% DFS at 2 years in pediatric and young adult patients with acute leukemia. The highest rates of success are observed in patients <10 years old and with pre-HSCT MRD < 0.1%. This approach, which has a lower incidence of acute/chronic GVHD and TRM in comparison with other donor cell sources, is particularly relevant for minority populations who have limited donor options. MRD, minimal residual disease; TCR, T-cell receptor.